Compare Stocks

→ “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$1.73 +1.2%	$1.70	$0.77 ▼ $14.00	$7.02M	1.48	5.06 million shs	139,362 shs
AZRX AzurRx BioPharma	$3.02 -3.2%	$4.04	$3.36 ▼ $26.30	$28.17M	1.51	628,703 shs	48,444 shs
CLRB Cellectar Biosciences	$3.02 -1.3%	$3.63	$1.33 ▼ $4.45	$97.43M	0.92	1.65 million shs	678,612 shs
EPIX ESSA Pharma	$6.12 -2.1%	$8.32	$2.56 ▼ $11.67	$270.75M	1.62	135,637 shs	64,765 shs
REXN Rexahn Pharmaceuticals		$2.06	$1.26 ▼ $4.26	$8.11M	0.98	162,968 shs	2,579 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	+1.17%	-20.28%	+26.74%	+36.76%	-79.65%
AZRX AzurRx BioPharma	-3.21%	+6.34%	-23.93%	-38.99%	+5.96%
CLRB Cellectar Biosciences	-1.31%	-0.66%	-21.56%	-19.47%	+106.71%
EPIX ESSA Pharma	-2.08%	-8.93%	-30.85%	-21.44%	+127.51%
REXN Rexahn Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)

Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.

Find out why right here (and see what you can do to get in too with just a few dollars).

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADIL Adial Pharmaceuticals	0.2059 of 5 stars	0.0	2.0	0.0	0.0	2.6	0.8	0.6
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLRB Cellectar Biosciences	2.2158 of 5 stars	3.5	4.0	0.0	0.0	2.5	0.0	0.6
EPIX ESSA Pharma	1.6866 of 5 stars	3.5	3.0	0.0	0.0	0.0	3.3	0.0
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A
CLRB Cellectar Biosciences	3.00	Buy	$20.00	562.25% Upside
EPIX ESSA Pharma	3.00	Buy	$16.50	169.61% Upside
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest AZRX, EPIX, ADIL, REXN, and CLRB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/28/2024	CLRB Cellectar Biosciences	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $28.00
3/28/2024	CLRB Cellectar Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $12.00
3/4/2024	CLRB Cellectar Biosciences	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$2.46 per share	N/A
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	($0.76) per share	N/A
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	($0.36) per share	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$3.30 per share	N/A
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	$2.48 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$5.12M	-$5.72	N/A	N/A	N/A	N/A	-250.52%	-183.24%	5/10/2024 (Estimated)
AZRX AzurRx BioPharma	-$32.67M	-$11.50	N/A	N/A	N/A	N/A	-482.96%	-258.47%	N/A
CLRB Cellectar Biosciences	-$37.98M	-$3.10	N/A	N/A	N/A	N/A	-3,821.29%	-280.23%	5/2/2024 (Estimated)
EPIX ESSA Pharma	-$26.58M	-$0.59	N/A	N/A	N/A	N/A	-17.41%	-17.04%	5/14/2024 (Estimated)
REXN Rexahn Pharmaceuticals	-$8.64M	N/A	0.00	N/A	N/A	N/A	-72.60%	-55.68%	N/A

Latest AZRX, EPIX, ADIL, REXN, and CLRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/27/2024	Q4 2023	CLRB Cellectar Biosciences	-$0.59	-$0.66	-$0.07	-$0.92	N/A	N/A
2/13/2024	12/31/2023	EPIX ESSA Pharma	-$0.17	-$0.14	+$0.03	-$0.14	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	4.90	4.90
AZRX AzurRx BioPharma	N/A	1.33	1.33
CLRB Cellectar Biosciences	N/A	0.81	0.81
EPIX ESSA Pharma	N/A	40.74	40.74
REXN Rexahn Pharmaceuticals	N/A	3.37	3.37

Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
AZRX AzurRx BioPharma	6.27%
CLRB Cellectar Biosciences	16.41%
EPIX ESSA Pharma	75.12%
REXN Rexahn Pharmaceuticals	7.49%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	14.47%
AZRX AzurRx BioPharma	7.30%
CLRB Cellectar Biosciences	4.60%
EPIX ESSA Pharma	14.70%
REXN Rexahn Pharmaceuticals	1.10%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	4	4.06 million	3.47 million	No Data
AZRX AzurRx BioPharma	12	9.33 million	8.65 million	Not Optionable
CLRB Cellectar Biosciences	20	32.26 million	30.78 million	Optionable
EPIX ESSA Pharma	50	44.24 million	37.74 million	Optionable
REXN Rexahn Pharmaceuticals	5	4.48 million	N/A	Optionable

AZRX, EPIX, ADIL, REXN, and CLRB Headlines

Source	Headline
	Aurinia Pharmaceuticals Inc AUPH morningstar.com - February 16 at 5:49 PM
	MaxCyte Appoints Douglas Swirsky as Chief Financial Officer benzinga.com - March 27 at 6:16 PM
	Rexahn: Holes Galore in Serdaxin Data thestreet.com - January 1 at 6:09 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adial Pharmaceuticals

NASDAQ:ADIL

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

AzurRx BioPharma

NASDAQ:AZRX

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

Cellectar Biosciences

NASDAQ:CLRB

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

ESSA Pharma

NASDAQ:EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Rexahn Pharmaceuticals

NASDAQ:REXN

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial